82 results
PRE 14A
LRMR
Larimar Therapeutics Inc
12 Apr 24
Preliminary proxy
6:06am
, which is presented to the Board for discussion. In addition, each Committee conducts an annual self-assessment in a review process similar … Meeting of Stockholders and 2024 Proxy Statement | 16
DIRECTOR COMPENSATION (continued)
In March 2024, the Board approved, based on Aon’s assessment
8-K
EX-99.1
dgh6kwc3tcpsiznrb ib
25 Mar 22
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
7:11am
8-K
EX-99.1
hjyi0 5jz
12 Aug 21
Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results
10:29am
8-K
EX-10.1
ga5qg7
21 May 21
Entry into a Material Definitive Agreement
9:30am
8-K
EX-99.1
0lcnuoj0
21 May 21
Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia
7:28am